0P8 Stock Chart & Stats
€282.40
€6.50(2.68%)
At close: 4:00 PM EST
€282.40
€6.50(2.68%)
Day’s Range― - ―
52-Week Range€193.10 - €306.40
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€10.95B
Enterprise Value€12.41B
Total Cash (Recent Filing)€241.29M
Total Debt (Recent Filing)€216.18M
Price to Earnings (P/E)72.7
Beta0.05
Next Earnings
Aug 04, 2026EPS Estimate
1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.38
Shares Outstanding39,331,425
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.48
Price to Sales (P/S)8.62
P/FCF Ratio69.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€316.86Price Target Upside12.20% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)4.34
Revenue Forecast (FY)€1.40B
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Market SharePenumbra's leading thrombectomy device has clinical evidence supporting conversion from drug therapy, which is likely to accelerate market share gains in thrombectomy and expand addressable patient volumes.
Product AdoptionStrong US adoption of the Ruby XL and new coil technology is driving embolization revenue growth and broadening the company's commercial base.
Strategic Acquisition SynergiesThe proposed acquisition by Boston Scientific aligns Penumbra's products with the buyer's cardiac portfolio, enabling synergies in peripheral thrombectomy and embolization and supporting a premium valuation.
Bears Say
Financing And Leverage ConcernsThe deal's use of cash, new debt and stock increases leverage for the combined company and could constrain financial flexibility after closing.
Limited Upside Due To Takeover DynamicsPending acquisition dynamics are expected to keep the stock trading near the agreed deal price, reducing standalone upside and prompting analyst rating downgrades.
Regulatory And Approval RiskA delay in regulatory approval for a key device has weighed on stroke-related sales and increases near-term revenue and execution uncertainty in the thrombectomy business.
Penumbra News
0P8 FAQ
What was Penumbra Inc.’s price range in the past 12 months?
Penumbra Inc. lowest stock price was €193.10 and its highest was €306.40 in the past 12 months.
What is Penumbra Inc.’s market cap?
Penumbra Inc.’s market cap is €10.95B.
When is Penumbra Inc.’s upcoming earnings report date?
Penumbra Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 31 days.
How were Penumbra Inc.’s earnings last quarter?
Penumbra Inc. released its earnings results on May 06, 2026. The company reported €0.717 earnings per share for the quarter, missing the consensus estimate of €0.907 by -€0.191.
Is Penumbra Inc. overvalued?
According to Wall Street analysts Penumbra Inc.’s price is currently Undervalued.
Does Penumbra Inc. pay dividends?
Penumbra Inc. does not currently pay dividends.
What is Penumbra Inc.’s EPS estimate?
Penumbra Inc.’s EPS estimate is 1.01.
How many shares outstanding does Penumbra Inc. have?
Penumbra Inc. has 39,331,425 shares outstanding.
What happened to Penumbra Inc.’s price movement after its last earnings report?
Penumbra Inc. reported an EPS of €0.717 in its last earnings report, missing expectations of €0.907. Following the earnings report the stock price went up 0.072%.
Which hedge fund is a major shareholder of Penumbra Inc.?
Currently, no hedge funds are holding shares in DE:0P8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Penumbra Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€316.86 (12.20% Upside)
€316.86 (12.20% Upside)
Blogger Sentiment
Bullish
DE:0P8 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.56%
12-Months-Change
Fundamentals
Return on Equity
12.32%
Trailing 12-Months
Asset Growth
19.15%
Trailing 12-Months
Company Description
Penumbra Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
0P8 Stock 12 Month Forecast
Average Price Target
€316.86
▲(12.20% Upside)
Technical Analysis
Options Prices
Currently, No data available
---











